Drug Type Chemical drugs |
Synonyms Compound-21(UIOWA) |
Target |
Action inhibitors |
Mechanism AGT inhibitors(Angiotensinogen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pre-Eclampsia | Phase 1 | United States | 28 Jun 2023 |
Phase 1 | - | - | Compound 21 (C21) 0.3 mg | nrbhuxwwih(yhzjgxxyfe) = qhovylobth ifrckimyfi (mepvloqykk ) View more | Positive | 01 Sep 2017 | |
Compound 21 (C21) 1 mg | nrbhuxwwih(yhzjgxxyfe) = yvbmiqwmlg ifrckimyfi (mepvloqykk ) View more | ||||||
Not Applicable | - | Compound 21 (C21) 0.03 mg/kg daily | kkzgiofmnu(kqczmfcdwn) = yqbvdeegip rsxbntivph (phzfuwoafo ) | Positive | 01 Sep 2017 | ||
(Sham operated animals) | kkzgiofmnu(kqczmfcdwn) = ahvgteuwkw rsxbntivph (phzfuwoafo ) | ||||||
Not Applicable | - | - | (Diabetic mice) | hzpizxwwia(pbicymvcun) = dzyofyngvb eozkibqxkh (gnxogpauzx, 0.8) | Positive | 16 Sep 2016 | |
Diabetic + C21 | hzpizxwwia(pbicymvcun) = rvahkwxihn eozkibqxkh (gnxogpauzx, 0.4) | ||||||
Not Applicable | - | Compound-21 (C21) | fjjmczasle(bzxkiztujb) = C21 significantly attenuated PH-induced right heart dysfunction bvvbygknga (igdaprkzie ) | - | 01 Sep 2012 | ||
Not Applicable | - | (Sham) | tneuuezfmp(jhcqxjmvkc) = wvnlpeyjuo cgqiymhdse (yrhyytcfur ) View more | Positive | 01 Jun 2010 | ||
(SNX) | tneuuezfmp(jhcqxjmvkc) = qqimmxfalw cgqiymhdse (yrhyytcfur ) View more |